rabbit anti ox1r antibody  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Alomone Labs rabbit anti ox1r antibody
    Paraventricular nucleus bilateral microinjection of <t>AAV2-OX1R-shRNA</t> significantly reduces OX1R expression within the brain. Following 3 weeks of DOCA-salt treatment, rat PVN areas were collected and subjected to either PCR analysis or immunostaining. mRNA levels of OX1R (A) were significantly reduced following OX1R knockdown ( n = 5; * p
    Rabbit Anti Ox1r Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti ox1r antibody/product/Alomone Labs
    Average 94 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    rabbit anti ox1r antibody - by Bioz Stars, 2022-10
    94/100 stars

    Images

    1) Product Images from "Activation of Orexin 1 Receptors in the Paraventricular Nucleus Contributes to the Development of Deoxycorticosterone Acetate-Salt Hypertension Through Regulation of Vasopressin"

    Article Title: Activation of Orexin 1 Receptors in the Paraventricular Nucleus Contributes to the Development of Deoxycorticosterone Acetate-Salt Hypertension Through Regulation of Vasopressin

    Journal: Frontiers in Physiology

    doi: 10.3389/fphys.2021.641331

    Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces OX1R expression within the brain. Following 3 weeks of DOCA-salt treatment, rat PVN areas were collected and subjected to either PCR analysis or immunostaining. mRNA levels of OX1R (A) were significantly reduced following OX1R knockdown ( n = 5; * p
    Figure Legend Snippet: Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces OX1R expression within the brain. Following 3 weeks of DOCA-salt treatment, rat PVN areas were collected and subjected to either PCR analysis or immunostaining. mRNA levels of OX1R (A) were significantly reduced following OX1R knockdown ( n = 5; * p

    Techniques Used: shRNA, Expressing, Polymerase Chain Reaction, Immunostaining

    Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces central production and subsequent peripheral release of AVP. Following 3 weeks of DOCA-salt treatment, brain PVN areas as well as plasma were collected to test AVP central expression and peripheral secretion. PVN OX1R knockdown ( n = 5) resulted in a significantly reduced PVN AVP mRNA expression (A) compared to DOCA-salt treated rats ( n = 9; * p
    Figure Legend Snippet: Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces central production and subsequent peripheral release of AVP. Following 3 weeks of DOCA-salt treatment, brain PVN areas as well as plasma were collected to test AVP central expression and peripheral secretion. PVN OX1R knockdown ( n = 5) resulted in a significantly reduced PVN AVP mRNA expression (A) compared to DOCA-salt treated rats ( n = 9; * p

    Techniques Used: shRNA, Expressing

    Chronic knockdown of OX1R in the PVN attenuates increased mean arterial pressure (MAP) induced by DOCA-salt treatment in SD rats. Rats were bilaterally injected with AAV2-OX1R-shRNA into the PVN 2 weeks prior to DOCA-salt treatment. Following this, blood pressure was monitored for 3 weeks during DOCA-salt treatment. Central knockdown of OX1R ( n = 4) within the PVN results in attenuation of mean arterial pressure compared to DOCA-salt treated rats ( n = 4; A ; * p
    Figure Legend Snippet: Chronic knockdown of OX1R in the PVN attenuates increased mean arterial pressure (MAP) induced by DOCA-salt treatment in SD rats. Rats were bilaterally injected with AAV2-OX1R-shRNA into the PVN 2 weeks prior to DOCA-salt treatment. Following this, blood pressure was monitored for 3 weeks during DOCA-salt treatment. Central knockdown of OX1R ( n = 4) within the PVN results in attenuation of mean arterial pressure compared to DOCA-salt treated rats ( n = 4; A ; * p

    Techniques Used: Injection, shRNA

    Deoxycorticosterone acetate (DOCA)-salt treatment increases orexin 1-receptor (OX1R) expression in the paraventricular nucleus (PVN) of Sprague Dawley (SD) rats. OX1R mRNA (A) and immunofluorescence (B) was compared in the PVN area between DOCA-salt treated ( n = 4) and vehicle control ( n = 3) rats. DOCA-salt treated rats showed a significant increase in OX1R expression within the PVN area ( * p
    Figure Legend Snippet: Deoxycorticosterone acetate (DOCA)-salt treatment increases orexin 1-receptor (OX1R) expression in the paraventricular nucleus (PVN) of Sprague Dawley (SD) rats. OX1R mRNA (A) and immunofluorescence (B) was compared in the PVN area between DOCA-salt treated ( n = 4) and vehicle control ( n = 3) rats. DOCA-salt treated rats showed a significant increase in OX1R expression within the PVN area ( * p

    Techniques Used: Expressing, Immunofluorescence

    The hypothesized relationship mediating the impact of central orexin system functioning on hypertension development in the DOCA-salt rat model. DOCA-salt treatment results in activation of circumventricular organs (CVOs), which send projections to the lateral hypothalamus (LH), stimulating Orexin A (OXA) release. OXA then interacts with OX1R at the PVN. This then facilitates an increased production and secretion of AVP to the periphery, where it causes increased blood pressure through various means including vasoconstriction, fluid reabsorption, and increased blood volume. CVO, circumventricular organs; LH, lateral hypothalamus; OXA, orexin-A; OX1R, orexin 1-receptor; PVN, paraventricular nucleus; and AVP, arginine vasopressin.
    Figure Legend Snippet: The hypothesized relationship mediating the impact of central orexin system functioning on hypertension development in the DOCA-salt rat model. DOCA-salt treatment results in activation of circumventricular organs (CVOs), which send projections to the lateral hypothalamus (LH), stimulating Orexin A (OXA) release. OXA then interacts with OX1R at the PVN. This then facilitates an increased production and secretion of AVP to the periphery, where it causes increased blood pressure through various means including vasoconstriction, fluid reabsorption, and increased blood volume. CVO, circumventricular organs; LH, lateral hypothalamus; OXA, orexin-A; OX1R, orexin 1-receptor; PVN, paraventricular nucleus; and AVP, arginine vasopressin.

    Techniques Used: Activation Assay

    2) Product Images from "Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension"

    Article Title: Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    doi: 10.1152/ajpheart.00822.2016

    A : representative immunostaining images of orexin receptor 1 (OX1R) in the paraventricular nucleus (PVN) between normal-salt (NS; 0.4% NaCl; left ) and high-salt (HS; 8% NaCl; right ) diet-fed Dahl salt-sensitive (Dahl S) rats. HS diet increased PVN OX1R immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative immunostaining images of arginine vasopressin (AVP) in the PVN between NS and HS diet-fed Dahl S rats. HS diet increased PVN AVP immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images (contrasts were adjusted to enhance immunostained clusters).
    Figure Legend Snippet: A : representative immunostaining images of orexin receptor 1 (OX1R) in the paraventricular nucleus (PVN) between normal-salt (NS; 0.4% NaCl; left ) and high-salt (HS; 8% NaCl; right ) diet-fed Dahl salt-sensitive (Dahl S) rats. HS diet increased PVN OX1R immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative immunostaining images of arginine vasopressin (AVP) in the PVN between NS and HS diet-fed Dahl S rats. HS diet increased PVN AVP immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images (contrasts were adjusted to enhance immunostained clusters).

    Techniques Used: Immunostaining

    A : representative images showing immunoreactivity of paraventricular nucleus (PVN) orexin receptor 1 (OX1R) 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult Sprague-Dawley SD rats. Intracerebroventricular hypertonic saline infusion increased PVN OX1R immunoreactivity. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative images showing PVN arginine vasopressin (AVP) expression 3 h after acute intracerebroventricular infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult SD rats. Intracerebroventricular NaCl solution increased PVN AVP immunoreactivity. The top row shows low-magnification images; the bottom row showss high-magnification images (contrast was adjusted to enhance immunostained clusters).
    Figure Legend Snippet: A : representative images showing immunoreactivity of paraventricular nucleus (PVN) orexin receptor 1 (OX1R) 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult Sprague-Dawley SD rats. Intracerebroventricular hypertonic saline infusion increased PVN OX1R immunoreactivity. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative images showing PVN arginine vasopressin (AVP) expression 3 h after acute intracerebroventricular infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult SD rats. Intracerebroventricular NaCl solution increased PVN AVP immunoreactivity. The top row shows low-magnification images; the bottom row showss high-magnification images (contrast was adjusted to enhance immunostained clusters).

    Techniques Used: Expressing

    Real-time PCR analysis of paraventricular nucleus (PVN) orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels at 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline) and hypertonic saline (4 μmol) using male adult Sprague-Dawley (SD) rats. Acute intracerebroventricular injection of hypertonic saline increased PVN OX1R and AVP mRNA levels in SD rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–7 for each group. * P ≤ 0.05 vs. vehicle control.
    Figure Legend Snippet: Real-time PCR analysis of paraventricular nucleus (PVN) orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels at 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline) and hypertonic saline (4 μmol) using male adult Sprague-Dawley (SD) rats. Acute intracerebroventricular injection of hypertonic saline increased PVN OX1R and AVP mRNA levels in SD rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–7 for each group. * P ≤ 0.05 vs. vehicle control.

    Techniques Used: Real-time Polymerase Chain Reaction, Expressing, Injection

    Real-time PCR analysis of orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels in the paraventricular nucleus (PVN) between normal salt (NS; 0.4% NaCl) and high salt (HS; 8% NaCl) diet-fed Sprague-Dawley (SD) rats and Dahl salt-sensitive (Dahl S) rats. HS diet did not change OX1R or OX2R but significantly increased AVP PVN mRNA expression in SD rats. HS diet increased mRNA levels of OX1R, OX2R, and AVP in the PVN in Dahl S rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–8 for each group. * P ≤ 0.05 vs. NS diet.
    Figure Legend Snippet: Real-time PCR analysis of orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels in the paraventricular nucleus (PVN) between normal salt (NS; 0.4% NaCl) and high salt (HS; 8% NaCl) diet-fed Sprague-Dawley (SD) rats and Dahl salt-sensitive (Dahl S) rats. HS diet did not change OX1R or OX2R but significantly increased AVP PVN mRNA expression in SD rats. HS diet increased mRNA levels of OX1R, OX2R, and AVP in the PVN in Dahl S rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–8 for each group. * P ≤ 0.05 vs. NS diet.

    Techniques Used: Real-time Polymerase Chain Reaction, Expressing

    3) Product Images from "Activation of Orexin System Stimulates CaMKII Expression"

    Article Title: Activation of Orexin System Stimulates CaMKII Expression

    Journal: Frontiers in Physiology

    doi: 10.3389/fphys.2021.698185

    Orexin-A treatment increases mRNA expression of CaMKII subunits in PC12-OX1R cells. (A) Orexin-A (100 nM) stimulation induced a time-dependent increase in mRNA expression of CaMKIIa (A1) and CaMKIIb (A2) subunits in PC12-OX1R cells. (B) Orexin-A (100 nM) treatment for 6 h induced increases in mRNA expression of CaMKIIa (B1) and CaMKIIb (B2) subunits in PC12-OX1R, but not in PC12 cells. (C) The effect of orexin-A on CaMKII expression is blocked by EGTA-AM. The data were normalized to GAPDH mRNA. Average control mRNA level was assigned as arbitrary unit 1 ( n = 6 per group, * P
    Figure Legend Snippet: Orexin-A treatment increases mRNA expression of CaMKII subunits in PC12-OX1R cells. (A) Orexin-A (100 nM) stimulation induced a time-dependent increase in mRNA expression of CaMKIIa (A1) and CaMKIIb (A2) subunits in PC12-OX1R cells. (B) Orexin-A (100 nM) treatment for 6 h induced increases in mRNA expression of CaMKIIa (B1) and CaMKIIb (B2) subunits in PC12-OX1R, but not in PC12 cells. (C) The effect of orexin-A on CaMKII expression is blocked by EGTA-AM. The data were normalized to GAPDH mRNA. Average control mRNA level was assigned as arbitrary unit 1 ( n = 6 per group, * P

    Techniques Used: Expressing

    PVN OX1R is primarily expressed in neurons in the SD rats. Representative images showing immunoreactivity of OX1R (green), neuronal nuclei NeuN [red (A) ], microglial marker Iba1 [red (B) ], astrocyte marker GFAP [red (C) ], and merged images in the PVN of SD rat. The area labeled in the dashed rectangle in the upper panel was magnified and showed in the lower panel. The brain coronal sections were taken from 1.8 mm caudal from the bregma. 3V, the third ventricle.
    Figure Legend Snippet: PVN OX1R is primarily expressed in neurons in the SD rats. Representative images showing immunoreactivity of OX1R (green), neuronal nuclei NeuN [red (A) ], microglial marker Iba1 [red (B) ], astrocyte marker GFAP [red (C) ], and merged images in the PVN of SD rat. The area labeled in the dashed rectangle in the upper panel was magnified and showed in the lower panel. The brain coronal sections were taken from 1.8 mm caudal from the bregma. 3V, the third ventricle.

    Techniques Used: Marker, Labeling

    Orexin-A treatment increases CaMKII activation in OX1R-expressing hypothalamic neurons. Hypothalamic neuronal cultures isolated from neonatal SD rats were treated with 1 μM of orexin-A or vehicle control for 15 min, then cells were subjected to immunostaining using primary antibody anti-phospho-CaMKII (P-CaMKII) or OX1R followed by incubation with fluorescent dye-labeled secondary antibody. (A) Orexin-A treatment increases P-CaMKII in hypothalamic neurons. The area labeled in a solid rectangle in the left panel was higher magnified in the right panel. (B) Representative images show the immunostaining of P-CaMKII (green), OX1R (red), and merged image in cultured PVN neurons under orexin-A treatment.
    Figure Legend Snippet: Orexin-A treatment increases CaMKII activation in OX1R-expressing hypothalamic neurons. Hypothalamic neuronal cultures isolated from neonatal SD rats were treated with 1 μM of orexin-A or vehicle control for 15 min, then cells were subjected to immunostaining using primary antibody anti-phospho-CaMKII (P-CaMKII) or OX1R followed by incubation with fluorescent dye-labeled secondary antibody. (A) Orexin-A treatment increases P-CaMKII in hypothalamic neurons. The area labeled in a solid rectangle in the left panel was higher magnified in the right panel. (B) Representative images show the immunostaining of P-CaMKII (green), OX1R (red), and merged image in cultured PVN neurons under orexin-A treatment.

    Techniques Used: Activation Assay, Expressing, Isolation, Immunostaining, Incubation, Labeling, Cell Culture

    Orexin-A treatment increases CaMKII subunits’ protein expression as well as CaMKII activation in PC12-OX1R cells. PC12-OX1R cells were incubated with 100 nM orexin-A for the indicated periods. Proteins were separated and probed with CaMKIIa, CaMKIIb, P-CamKII, and β-actin antibodies. (A) Orexin-A treatment increases CaMKII protein expression in a time-dependent manner. (A1) Representative western blots showing CaMKIIa, CaMKIIb, and β-actin in orexin-A treated and control cells. Quantification of CaMKIIa (A2) and CaMKIIb (A3) that has been normalized against β-actin and compared with control, normalized to unity ( n = 6, * P
    Figure Legend Snippet: Orexin-A treatment increases CaMKII subunits’ protein expression as well as CaMKII activation in PC12-OX1R cells. PC12-OX1R cells were incubated with 100 nM orexin-A for the indicated periods. Proteins were separated and probed with CaMKIIa, CaMKIIb, P-CamKII, and β-actin antibodies. (A) Orexin-A treatment increases CaMKII protein expression in a time-dependent manner. (A1) Representative western blots showing CaMKIIa, CaMKIIb, and β-actin in orexin-A treated and control cells. Quantification of CaMKIIa (A2) and CaMKIIb (A3) that has been normalized against β-actin and compared with control, normalized to unity ( n = 6, * P

    Techniques Used: Expressing, Activation Assay, Incubation, Western Blot

    A proposed mechanism that OX1R activation on sympathetic nerve activity and blood pressure regulation. Binding of orexin-A with OX1R results in OX1R activation, which in turn triggers the influx of Ca 2+ resulting in intracellular Ca 2+ increase. Ca 2+ , in turn, activates CaMKII enzyme activity as well as CaMKII expression, which eventually results in SNA increase and blood pressure elevation.
    Figure Legend Snippet: A proposed mechanism that OX1R activation on sympathetic nerve activity and blood pressure regulation. Binding of orexin-A with OX1R results in OX1R activation, which in turn triggers the influx of Ca 2+ resulting in intracellular Ca 2+ increase. Ca 2+ , in turn, activates CaMKII enzyme activity as well as CaMKII expression, which eventually results in SNA increase and blood pressure elevation.

    Techniques Used: Activation Assay, Activity Assay, Binding Assay, Expressing

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs rabbit anti ox1r antibody
    Paraventricular nucleus bilateral microinjection of <t>AAV2-OX1R-shRNA</t> significantly reduces OX1R expression within the brain. Following 3 weeks of DOCA-salt treatment, rat PVN areas were collected and subjected to either PCR analysis or immunostaining. mRNA levels of OX1R (A) were significantly reduced following OX1R knockdown ( n = 5; * p
    Rabbit Anti Ox1r Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti ox1r antibody/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti ox1r antibody - by Bioz Stars, 2022-10
    94/100 stars
      Buy from Supplier

    90
    Alomone Labs primary antibodies rabbit anti ox1r
    Activation of PVN <t>OX1R</t> receptors increases sympathetic nerve activity (SNA). (A) Summary data show changes in SSNA, RSNA, MAP and HR in response to PVN bilateral microinjections of DMSO + orexin A (n = 5) or SB408124 + orexin A (n = 5) in SD rats. (B) Representative traces showing SSNA, RSNA and MAP responses to bilateral microinjection of DMSO + orexin A (25 pmol) (left), or SB408124 (300 pmol) + orexin A (25 pmol) (right) into PVN in two individual SD rats respectively. (C) Left: 2.5-second specimen traces of SSNA (top) and RSNA (bottom) before and after orexin A microinjection into the PVN in rat receiving DMSO + orexin A microinjection. (C) Right: 2.5-second specimen traces of SSNA (top) and RSNA (bottom) before and after injection of orexin A into PVN in rat receiving SB408124 + orexin A injection. SSNA, splanchnic SNA; RSNA, renal SNA; MAP, mean arterial blood pressure; HR, heart rate; HB, hexamethonium bromide; † P
    Primary Antibodies Rabbit Anti Ox1r, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies rabbit anti ox1r/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies rabbit anti ox1r - by Bioz Stars, 2022-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces OX1R expression within the brain. Following 3 weeks of DOCA-salt treatment, rat PVN areas were collected and subjected to either PCR analysis or immunostaining. mRNA levels of OX1R (A) were significantly reduced following OX1R knockdown ( n = 5; * p

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin 1 Receptors in the Paraventricular Nucleus Contributes to the Development of Deoxycorticosterone Acetate-Salt Hypertension Through Regulation of Vasopressin

    doi: 10.3389/fphys.2021.641331

    Figure Lengend Snippet: Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces OX1R expression within the brain. Following 3 weeks of DOCA-salt treatment, rat PVN areas were collected and subjected to either PCR analysis or immunostaining. mRNA levels of OX1R (A) were significantly reduced following OX1R knockdown ( n = 5; * p

    Article Snippet: Following wash in 1xPBS 3 times for 10 min each, brain sections were incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:300 dilution), rabbit anti-AVP antibody (OriGene Technologies, United States, 1:400 dilution), or mouse anti-OXA antibody (Abcam, United States, 1:300 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: shRNA, Expressing, Polymerase Chain Reaction, Immunostaining

    Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces central production and subsequent peripheral release of AVP. Following 3 weeks of DOCA-salt treatment, brain PVN areas as well as plasma were collected to test AVP central expression and peripheral secretion. PVN OX1R knockdown ( n = 5) resulted in a significantly reduced PVN AVP mRNA expression (A) compared to DOCA-salt treated rats ( n = 9; * p

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin 1 Receptors in the Paraventricular Nucleus Contributes to the Development of Deoxycorticosterone Acetate-Salt Hypertension Through Regulation of Vasopressin

    doi: 10.3389/fphys.2021.641331

    Figure Lengend Snippet: Paraventricular nucleus bilateral microinjection of AAV2-OX1R-shRNA significantly reduces central production and subsequent peripheral release of AVP. Following 3 weeks of DOCA-salt treatment, brain PVN areas as well as plasma were collected to test AVP central expression and peripheral secretion. PVN OX1R knockdown ( n = 5) resulted in a significantly reduced PVN AVP mRNA expression (A) compared to DOCA-salt treated rats ( n = 9; * p

    Article Snippet: Following wash in 1xPBS 3 times for 10 min each, brain sections were incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:300 dilution), rabbit anti-AVP antibody (OriGene Technologies, United States, 1:400 dilution), or mouse anti-OXA antibody (Abcam, United States, 1:300 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: shRNA, Expressing

    Chronic knockdown of OX1R in the PVN attenuates increased mean arterial pressure (MAP) induced by DOCA-salt treatment in SD rats. Rats were bilaterally injected with AAV2-OX1R-shRNA into the PVN 2 weeks prior to DOCA-salt treatment. Following this, blood pressure was monitored for 3 weeks during DOCA-salt treatment. Central knockdown of OX1R ( n = 4) within the PVN results in attenuation of mean arterial pressure compared to DOCA-salt treated rats ( n = 4; A ; * p

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin 1 Receptors in the Paraventricular Nucleus Contributes to the Development of Deoxycorticosterone Acetate-Salt Hypertension Through Regulation of Vasopressin

    doi: 10.3389/fphys.2021.641331

    Figure Lengend Snippet: Chronic knockdown of OX1R in the PVN attenuates increased mean arterial pressure (MAP) induced by DOCA-salt treatment in SD rats. Rats were bilaterally injected with AAV2-OX1R-shRNA into the PVN 2 weeks prior to DOCA-salt treatment. Following this, blood pressure was monitored for 3 weeks during DOCA-salt treatment. Central knockdown of OX1R ( n = 4) within the PVN results in attenuation of mean arterial pressure compared to DOCA-salt treated rats ( n = 4; A ; * p

    Article Snippet: Following wash in 1xPBS 3 times for 10 min each, brain sections were incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:300 dilution), rabbit anti-AVP antibody (OriGene Technologies, United States, 1:400 dilution), or mouse anti-OXA antibody (Abcam, United States, 1:300 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: Injection, shRNA

    Deoxycorticosterone acetate (DOCA)-salt treatment increases orexin 1-receptor (OX1R) expression in the paraventricular nucleus (PVN) of Sprague Dawley (SD) rats. OX1R mRNA (A) and immunofluorescence (B) was compared in the PVN area between DOCA-salt treated ( n = 4) and vehicle control ( n = 3) rats. DOCA-salt treated rats showed a significant increase in OX1R expression within the PVN area ( * p

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin 1 Receptors in the Paraventricular Nucleus Contributes to the Development of Deoxycorticosterone Acetate-Salt Hypertension Through Regulation of Vasopressin

    doi: 10.3389/fphys.2021.641331

    Figure Lengend Snippet: Deoxycorticosterone acetate (DOCA)-salt treatment increases orexin 1-receptor (OX1R) expression in the paraventricular nucleus (PVN) of Sprague Dawley (SD) rats. OX1R mRNA (A) and immunofluorescence (B) was compared in the PVN area between DOCA-salt treated ( n = 4) and vehicle control ( n = 3) rats. DOCA-salt treated rats showed a significant increase in OX1R expression within the PVN area ( * p

    Article Snippet: Following wash in 1xPBS 3 times for 10 min each, brain sections were incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:300 dilution), rabbit anti-AVP antibody (OriGene Technologies, United States, 1:400 dilution), or mouse anti-OXA antibody (Abcam, United States, 1:300 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: Expressing, Immunofluorescence

    The hypothesized relationship mediating the impact of central orexin system functioning on hypertension development in the DOCA-salt rat model. DOCA-salt treatment results in activation of circumventricular organs (CVOs), which send projections to the lateral hypothalamus (LH), stimulating Orexin A (OXA) release. OXA then interacts with OX1R at the PVN. This then facilitates an increased production and secretion of AVP to the periphery, where it causes increased blood pressure through various means including vasoconstriction, fluid reabsorption, and increased blood volume. CVO, circumventricular organs; LH, lateral hypothalamus; OXA, orexin-A; OX1R, orexin 1-receptor; PVN, paraventricular nucleus; and AVP, arginine vasopressin.

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin 1 Receptors in the Paraventricular Nucleus Contributes to the Development of Deoxycorticosterone Acetate-Salt Hypertension Through Regulation of Vasopressin

    doi: 10.3389/fphys.2021.641331

    Figure Lengend Snippet: The hypothesized relationship mediating the impact of central orexin system functioning on hypertension development in the DOCA-salt rat model. DOCA-salt treatment results in activation of circumventricular organs (CVOs), which send projections to the lateral hypothalamus (LH), stimulating Orexin A (OXA) release. OXA then interacts with OX1R at the PVN. This then facilitates an increased production and secretion of AVP to the periphery, where it causes increased blood pressure through various means including vasoconstriction, fluid reabsorption, and increased blood volume. CVO, circumventricular organs; LH, lateral hypothalamus; OXA, orexin-A; OX1R, orexin 1-receptor; PVN, paraventricular nucleus; and AVP, arginine vasopressin.

    Article Snippet: Following wash in 1xPBS 3 times for 10 min each, brain sections were incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:300 dilution), rabbit anti-AVP antibody (OriGene Technologies, United States, 1:400 dilution), or mouse anti-OXA antibody (Abcam, United States, 1:300 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: Activation Assay

    A : representative immunostaining images of orexin receptor 1 (OX1R) in the paraventricular nucleus (PVN) between normal-salt (NS; 0.4% NaCl; left ) and high-salt (HS; 8% NaCl; right ) diet-fed Dahl salt-sensitive (Dahl S) rats. HS diet increased PVN OX1R immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative immunostaining images of arginine vasopressin (AVP) in the PVN between NS and HS diet-fed Dahl S rats. HS diet increased PVN AVP immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images (contrasts were adjusted to enhance immunostained clusters).

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension

    doi: 10.1152/ajpheart.00822.2016

    Figure Lengend Snippet: A : representative immunostaining images of orexin receptor 1 (OX1R) in the paraventricular nucleus (PVN) between normal-salt (NS; 0.4% NaCl; left ) and high-salt (HS; 8% NaCl; right ) diet-fed Dahl salt-sensitive (Dahl S) rats. HS diet increased PVN OX1R immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative immunostaining images of arginine vasopressin (AVP) in the PVN between NS and HS diet-fed Dahl S rats. HS diet increased PVN AVP immunoreactivity in Dahl S rats. The top row shows low-magnification images; the bottom row shows high-magnification images (contrasts were adjusted to enhance immunostained clusters).

    Article Snippet: Brain sections were then incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:500 dilution) or rabbit anti-AVP antibody (1:500 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: Immunostaining

    A : representative images showing immunoreactivity of paraventricular nucleus (PVN) orexin receptor 1 (OX1R) 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult Sprague-Dawley SD rats. Intracerebroventricular hypertonic saline infusion increased PVN OX1R immunoreactivity. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative images showing PVN arginine vasopressin (AVP) expression 3 h after acute intracerebroventricular infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult SD rats. Intracerebroventricular NaCl solution increased PVN AVP immunoreactivity. The top row shows low-magnification images; the bottom row showss high-magnification images (contrast was adjusted to enhance immunostained clusters).

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension

    doi: 10.1152/ajpheart.00822.2016

    Figure Lengend Snippet: A : representative images showing immunoreactivity of paraventricular nucleus (PVN) orexin receptor 1 (OX1R) 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult Sprague-Dawley SD rats. Intracerebroventricular hypertonic saline infusion increased PVN OX1R immunoreactivity. The top row shows low-magnification images; the bottom row shows high-magnification images. B : representative images showing PVN arginine vasopressin (AVP) expression 3 h after acute intracerebroventricular infusion of vehicle control (0.9% saline; left ) and hypertonic saline (4 μmol; right ) using male adult SD rats. Intracerebroventricular NaCl solution increased PVN AVP immunoreactivity. The top row shows low-magnification images; the bottom row showss high-magnification images (contrast was adjusted to enhance immunostained clusters).

    Article Snippet: Brain sections were then incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:500 dilution) or rabbit anti-AVP antibody (1:500 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: Expressing

    Real-time PCR analysis of paraventricular nucleus (PVN) orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels at 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline) and hypertonic saline (4 μmol) using male adult Sprague-Dawley (SD) rats. Acute intracerebroventricular injection of hypertonic saline increased PVN OX1R and AVP mRNA levels in SD rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–7 for each group. * P ≤ 0.05 vs. vehicle control.

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension

    doi: 10.1152/ajpheart.00822.2016

    Figure Lengend Snippet: Real-time PCR analysis of paraventricular nucleus (PVN) orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels at 3 h after acute intracerebroventricular (ICV) infusion of vehicle control (0.9% saline) and hypertonic saline (4 μmol) using male adult Sprague-Dawley (SD) rats. Acute intracerebroventricular injection of hypertonic saline increased PVN OX1R and AVP mRNA levels in SD rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–7 for each group. * P ≤ 0.05 vs. vehicle control.

    Article Snippet: Brain sections were then incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:500 dilution) or rabbit anti-AVP antibody (1:500 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: Real-time Polymerase Chain Reaction, Expressing, Injection

    Real-time PCR analysis of orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels in the paraventricular nucleus (PVN) between normal salt (NS; 0.4% NaCl) and high salt (HS; 8% NaCl) diet-fed Sprague-Dawley (SD) rats and Dahl salt-sensitive (Dahl S) rats. HS diet did not change OX1R or OX2R but significantly increased AVP PVN mRNA expression in SD rats. HS diet increased mRNA levels of OX1R, OX2R, and AVP in the PVN in Dahl S rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–8 for each group. * P ≤ 0.05 vs. NS diet.

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension

    doi: 10.1152/ajpheart.00822.2016

    Figure Lengend Snippet: Real-time PCR analysis of orexin receptor 1 (OX1R), orexin receptor 2 (OX2R), and arginine vasopressin (AVP) mRNA expression levels in the paraventricular nucleus (PVN) between normal salt (NS; 0.4% NaCl) and high salt (HS; 8% NaCl) diet-fed Sprague-Dawley (SD) rats and Dahl salt-sensitive (Dahl S) rats. HS diet did not change OX1R or OX2R but significantly increased AVP PVN mRNA expression in SD rats. HS diet increased mRNA levels of OX1R, OX2R, and AVP in the PVN in Dahl S rats. The mRNA level in the control sample was assigned to equal 1 arbitrary unit. n = 4–8 for each group. * P ≤ 0.05 vs. NS diet.

    Article Snippet: Brain sections were then incubated with either rabbit anti-OX1R antibody (Alomon Laboratories, Jerusalem, Israel, 1:500 dilution) or rabbit anti-AVP antibody (1:500 dilution) in PBS containing 0.5% Triton X-100 and 5% horse serum for 72 h at 4°C.

    Techniques: Real-time Polymerase Chain Reaction, Expressing

    Orexin-A treatment increases mRNA expression of CaMKII subunits in PC12-OX1R cells. (A) Orexin-A (100 nM) stimulation induced a time-dependent increase in mRNA expression of CaMKIIa (A1) and CaMKIIb (A2) subunits in PC12-OX1R cells. (B) Orexin-A (100 nM) treatment for 6 h induced increases in mRNA expression of CaMKIIa (B1) and CaMKIIb (B2) subunits in PC12-OX1R, but not in PC12 cells. (C) The effect of orexin-A on CaMKII expression is blocked by EGTA-AM. The data were normalized to GAPDH mRNA. Average control mRNA level was assigned as arbitrary unit 1 ( n = 6 per group, * P

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin System Stimulates CaMKII Expression

    doi: 10.3389/fphys.2021.698185

    Figure Lengend Snippet: Orexin-A treatment increases mRNA expression of CaMKII subunits in PC12-OX1R cells. (A) Orexin-A (100 nM) stimulation induced a time-dependent increase in mRNA expression of CaMKIIa (A1) and CaMKIIb (A2) subunits in PC12-OX1R cells. (B) Orexin-A (100 nM) treatment for 6 h induced increases in mRNA expression of CaMKIIa (B1) and CaMKIIb (B2) subunits in PC12-OX1R, but not in PC12 cells. (C) The effect of orexin-A on CaMKII expression is blocked by EGTA-AM. The data were normalized to GAPDH mRNA. Average control mRNA level was assigned as arbitrary unit 1 ( n = 6 per group, * P

    Article Snippet: Goat anti-OX1R antibody was purchased from OriGene Technologies (Rockville, MD, United States); rabbit anti-OX1R antibody was a product of Alomone Labs (Jerusalem, Israel); rabbit anti-NeuN and rabbit anti-GFAP antibodies were products of Cell Signaling Technology (Danvers, MA, United States); rabbit anti-Iba1 antibody was purchased from Wako; Primary antibodies mouse anti-CaMKIIa, mouse anti-CaMKIIb, and mouse anti-P-CaMKII were products of Santa Cruz Biotechnology (Dallas TX, United States).

    Techniques: Expressing

    PVN OX1R is primarily expressed in neurons in the SD rats. Representative images showing immunoreactivity of OX1R (green), neuronal nuclei NeuN [red (A) ], microglial marker Iba1 [red (B) ], astrocyte marker GFAP [red (C) ], and merged images in the PVN of SD rat. The area labeled in the dashed rectangle in the upper panel was magnified and showed in the lower panel. The brain coronal sections were taken from 1.8 mm caudal from the bregma. 3V, the third ventricle.

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin System Stimulates CaMKII Expression

    doi: 10.3389/fphys.2021.698185

    Figure Lengend Snippet: PVN OX1R is primarily expressed in neurons in the SD rats. Representative images showing immunoreactivity of OX1R (green), neuronal nuclei NeuN [red (A) ], microglial marker Iba1 [red (B) ], astrocyte marker GFAP [red (C) ], and merged images in the PVN of SD rat. The area labeled in the dashed rectangle in the upper panel was magnified and showed in the lower panel. The brain coronal sections were taken from 1.8 mm caudal from the bregma. 3V, the third ventricle.

    Article Snippet: Goat anti-OX1R antibody was purchased from OriGene Technologies (Rockville, MD, United States); rabbit anti-OX1R antibody was a product of Alomone Labs (Jerusalem, Israel); rabbit anti-NeuN and rabbit anti-GFAP antibodies were products of Cell Signaling Technology (Danvers, MA, United States); rabbit anti-Iba1 antibody was purchased from Wako; Primary antibodies mouse anti-CaMKIIa, mouse anti-CaMKIIb, and mouse anti-P-CaMKII were products of Santa Cruz Biotechnology (Dallas TX, United States).

    Techniques: Marker, Labeling

    Orexin-A treatment increases CaMKII activation in OX1R-expressing hypothalamic neurons. Hypothalamic neuronal cultures isolated from neonatal SD rats were treated with 1 μM of orexin-A or vehicle control for 15 min, then cells were subjected to immunostaining using primary antibody anti-phospho-CaMKII (P-CaMKII) or OX1R followed by incubation with fluorescent dye-labeled secondary antibody. (A) Orexin-A treatment increases P-CaMKII in hypothalamic neurons. The area labeled in a solid rectangle in the left panel was higher magnified in the right panel. (B) Representative images show the immunostaining of P-CaMKII (green), OX1R (red), and merged image in cultured PVN neurons under orexin-A treatment.

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin System Stimulates CaMKII Expression

    doi: 10.3389/fphys.2021.698185

    Figure Lengend Snippet: Orexin-A treatment increases CaMKII activation in OX1R-expressing hypothalamic neurons. Hypothalamic neuronal cultures isolated from neonatal SD rats were treated with 1 μM of orexin-A or vehicle control for 15 min, then cells were subjected to immunostaining using primary antibody anti-phospho-CaMKII (P-CaMKII) or OX1R followed by incubation with fluorescent dye-labeled secondary antibody. (A) Orexin-A treatment increases P-CaMKII in hypothalamic neurons. The area labeled in a solid rectangle in the left panel was higher magnified in the right panel. (B) Representative images show the immunostaining of P-CaMKII (green), OX1R (red), and merged image in cultured PVN neurons under orexin-A treatment.

    Article Snippet: Goat anti-OX1R antibody was purchased from OriGene Technologies (Rockville, MD, United States); rabbit anti-OX1R antibody was a product of Alomone Labs (Jerusalem, Israel); rabbit anti-NeuN and rabbit anti-GFAP antibodies were products of Cell Signaling Technology (Danvers, MA, United States); rabbit anti-Iba1 antibody was purchased from Wako; Primary antibodies mouse anti-CaMKIIa, mouse anti-CaMKIIb, and mouse anti-P-CaMKII were products of Santa Cruz Biotechnology (Dallas TX, United States).

    Techniques: Activation Assay, Expressing, Isolation, Immunostaining, Incubation, Labeling, Cell Culture

    Orexin-A treatment increases CaMKII subunits’ protein expression as well as CaMKII activation in PC12-OX1R cells. PC12-OX1R cells were incubated with 100 nM orexin-A for the indicated periods. Proteins were separated and probed with CaMKIIa, CaMKIIb, P-CamKII, and β-actin antibodies. (A) Orexin-A treatment increases CaMKII protein expression in a time-dependent manner. (A1) Representative western blots showing CaMKIIa, CaMKIIb, and β-actin in orexin-A treated and control cells. Quantification of CaMKIIa (A2) and CaMKIIb (A3) that has been normalized against β-actin and compared with control, normalized to unity ( n = 6, * P

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin System Stimulates CaMKII Expression

    doi: 10.3389/fphys.2021.698185

    Figure Lengend Snippet: Orexin-A treatment increases CaMKII subunits’ protein expression as well as CaMKII activation in PC12-OX1R cells. PC12-OX1R cells were incubated with 100 nM orexin-A for the indicated periods. Proteins were separated and probed with CaMKIIa, CaMKIIb, P-CamKII, and β-actin antibodies. (A) Orexin-A treatment increases CaMKII protein expression in a time-dependent manner. (A1) Representative western blots showing CaMKIIa, CaMKIIb, and β-actin in orexin-A treated and control cells. Quantification of CaMKIIa (A2) and CaMKIIb (A3) that has been normalized against β-actin and compared with control, normalized to unity ( n = 6, * P

    Article Snippet: Goat anti-OX1R antibody was purchased from OriGene Technologies (Rockville, MD, United States); rabbit anti-OX1R antibody was a product of Alomone Labs (Jerusalem, Israel); rabbit anti-NeuN and rabbit anti-GFAP antibodies were products of Cell Signaling Technology (Danvers, MA, United States); rabbit anti-Iba1 antibody was purchased from Wako; Primary antibodies mouse anti-CaMKIIa, mouse anti-CaMKIIb, and mouse anti-P-CaMKII were products of Santa Cruz Biotechnology (Dallas TX, United States).

    Techniques: Expressing, Activation Assay, Incubation, Western Blot

    A proposed mechanism that OX1R activation on sympathetic nerve activity and blood pressure regulation. Binding of orexin-A with OX1R results in OX1R activation, which in turn triggers the influx of Ca 2+ resulting in intracellular Ca 2+ increase. Ca 2+ , in turn, activates CaMKII enzyme activity as well as CaMKII expression, which eventually results in SNA increase and blood pressure elevation.

    Journal: Frontiers in Physiology

    Article Title: Activation of Orexin System Stimulates CaMKII Expression

    doi: 10.3389/fphys.2021.698185

    Figure Lengend Snippet: A proposed mechanism that OX1R activation on sympathetic nerve activity and blood pressure regulation. Binding of orexin-A with OX1R results in OX1R activation, which in turn triggers the influx of Ca 2+ resulting in intracellular Ca 2+ increase. Ca 2+ , in turn, activates CaMKII enzyme activity as well as CaMKII expression, which eventually results in SNA increase and blood pressure elevation.

    Article Snippet: Goat anti-OX1R antibody was purchased from OriGene Technologies (Rockville, MD, United States); rabbit anti-OX1R antibody was a product of Alomone Labs (Jerusalem, Israel); rabbit anti-NeuN and rabbit anti-GFAP antibodies were products of Cell Signaling Technology (Danvers, MA, United States); rabbit anti-Iba1 antibody was purchased from Wako; Primary antibodies mouse anti-CaMKIIa, mouse anti-CaMKIIb, and mouse anti-P-CaMKII were products of Santa Cruz Biotechnology (Dallas TX, United States).

    Techniques: Activation Assay, Activity Assay, Binding Assay, Expressing

    Activation of PVN OX1R receptors increases sympathetic nerve activity (SNA). (A) Summary data show changes in SSNA, RSNA, MAP and HR in response to PVN bilateral microinjections of DMSO + orexin A (n = 5) or SB408124 + orexin A (n = 5) in SD rats. (B) Representative traces showing SSNA, RSNA and MAP responses to bilateral microinjection of DMSO + orexin A (25 pmol) (left), or SB408124 (300 pmol) + orexin A (25 pmol) (right) into PVN in two individual SD rats respectively. (C) Left: 2.5-second specimen traces of SSNA (top) and RSNA (bottom) before and after orexin A microinjection into the PVN in rat receiving DMSO + orexin A microinjection. (C) Right: 2.5-second specimen traces of SSNA (top) and RSNA (bottom) before and after injection of orexin A into PVN in rat receiving SB408124 + orexin A injection. SSNA, splanchnic SNA; RSNA, renal SNA; MAP, mean arterial blood pressure; HR, heart rate; HB, hexamethonium bromide; † P

    Journal: Acta physiologica (Oxford, England)

    Article Title: Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats

    doi: 10.1111/apha.12963

    Figure Lengend Snippet: Activation of PVN OX1R receptors increases sympathetic nerve activity (SNA). (A) Summary data show changes in SSNA, RSNA, MAP and HR in response to PVN bilateral microinjections of DMSO + orexin A (n = 5) or SB408124 + orexin A (n = 5) in SD rats. (B) Representative traces showing SSNA, RSNA and MAP responses to bilateral microinjection of DMSO + orexin A (25 pmol) (left), or SB408124 (300 pmol) + orexin A (25 pmol) (right) into PVN in two individual SD rats respectively. (C) Left: 2.5-second specimen traces of SSNA (top) and RSNA (bottom) before and after orexin A microinjection into the PVN in rat receiving DMSO + orexin A microinjection. (C) Right: 2.5-second specimen traces of SSNA (top) and RSNA (bottom) before and after injection of orexin A into PVN in rat receiving SB408124 + orexin A injection. SSNA, splanchnic SNA; RSNA, renal SNA; MAP, mean arterial blood pressure; HR, heart rate; HB, hexamethonium bromide; † P

    Article Snippet: Primary antibodies rabbit anti-OX1R and rabbit anti-OX2R were products of Alomone laboratories (Jerusalem, Israel); mouse anti-Fra1 antibody and mouse anti-TNFα antibody were from Santa Cruz Biotechnology.

    Techniques: Activation Assay, Activity Assay, Injection

    Orexin A (100 nmol L −1 ) treatment enhances immunoreactivity of TNF -α in PC12-OX1R cells. (A) The pictures show the DAPI staining (blue) and TNF -α staining (green) from cells in control and orexin A treatment group respectively. (B) The bar graph showing the summary data of the TNF -α expression in cells from control and orexin A treatment group. †† P

    Journal: Acta physiologica (Oxford, England)

    Article Title: Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats

    doi: 10.1111/apha.12963

    Figure Lengend Snippet: Orexin A (100 nmol L −1 ) treatment enhances immunoreactivity of TNF -α in PC12-OX1R cells. (A) The pictures show the DAPI staining (blue) and TNF -α staining (green) from cells in control and orexin A treatment group respectively. (B) The bar graph showing the summary data of the TNF -α expression in cells from control and orexin A treatment group. †† P

    Article Snippet: Primary antibodies rabbit anti-OX1R and rabbit anti-OX2R were products of Alomone laboratories (Jerusalem, Israel); mouse anti-Fra1 antibody and mouse anti-TNFα antibody were from Santa Cruz Biotechnology.

    Techniques: Staining, Expressing

    Orexin A (100 nmol L −1 ) treatment increases immunoreactivity of Fra1 in PC12-OX1R cells. (A) The pictures show the DAPI staining (blue) and Fra1 staining (green) from cells in control and orexin A treatment group respectively. (B) The bar graph showing the summary data of statistical analysis of the Fra1 expression in cells from control and orexin A treatment group. †† P

    Journal: Acta physiologica (Oxford, England)

    Article Title: Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats

    doi: 10.1111/apha.12963

    Figure Lengend Snippet: Orexin A (100 nmol L −1 ) treatment increases immunoreactivity of Fra1 in PC12-OX1R cells. (A) The pictures show the DAPI staining (blue) and Fra1 staining (green) from cells in control and orexin A treatment group respectively. (B) The bar graph showing the summary data of statistical analysis of the Fra1 expression in cells from control and orexin A treatment group. †† P

    Article Snippet: Primary antibodies rabbit anti-OX1R and rabbit anti-OX2R were products of Alomone laboratories (Jerusalem, Israel); mouse anti-Fra1 antibody and mouse anti-TNFα antibody were from Santa Cruz Biotechnology.

    Techniques: Staining, Expressing

    Colocalization of OX1R and Fra1 in the paraventricular nucleus (PVN). (A) a representative micrograph showing immunoreactivity of OX1R (green), Fra1 (red) and merged image in the PVN of vehicle control rat; (B) a representative micrograph showing immunoreactivity of OX1R (green), Fra1(red) and merged image in the PVN of central administration of orexin A SD rat. The brain coronal sections were taken from bregma −1.6 mm. 3V, the third ventricle

    Journal: Acta physiologica (Oxford, England)

    Article Title: Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats

    doi: 10.1111/apha.12963

    Figure Lengend Snippet: Colocalization of OX1R and Fra1 in the paraventricular nucleus (PVN). (A) a representative micrograph showing immunoreactivity of OX1R (green), Fra1 (red) and merged image in the PVN of vehicle control rat; (B) a representative micrograph showing immunoreactivity of OX1R (green), Fra1(red) and merged image in the PVN of central administration of orexin A SD rat. The brain coronal sections were taken from bregma −1.6 mm. 3V, the third ventricle

    Article Snippet: Primary antibodies rabbit anti-OX1R and rabbit anti-OX2R were products of Alomone laboratories (Jerusalem, Israel); mouse anti-Fra1 antibody and mouse anti-TNFα antibody were from Santa Cruz Biotechnology.

    Techniques:

    OX1R is expressed in RVLM-projecting PVN neurons. (A) A representative micrograph showing immunoreactivity of OX1R (green), tracer labelled RVLM-projecting PVN neurons (red) and merged micrograph of OX1R and tracer in the PVN. (B) Higher magnification micrograph for the area boxed in image (A). The arrows show the OX1R-expressing neurons which have axons projecting to the RVLM. The brain section is taken from about bregma −1.6 mm. 3V, the third ventricle

    Journal: Acta physiologica (Oxford, England)

    Article Title: Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats

    doi: 10.1111/apha.12963

    Figure Lengend Snippet: OX1R is expressed in RVLM-projecting PVN neurons. (A) A representative micrograph showing immunoreactivity of OX1R (green), tracer labelled RVLM-projecting PVN neurons (red) and merged micrograph of OX1R and tracer in the PVN. (B) Higher magnification micrograph for the area boxed in image (A). The arrows show the OX1R-expressing neurons which have axons projecting to the RVLM. The brain section is taken from about bregma −1.6 mm. 3V, the third ventricle

    Article Snippet: Primary antibodies rabbit anti-OX1R and rabbit anti-OX2R were products of Alomone laboratories (Jerusalem, Israel); mouse anti-Fra1 antibody and mouse anti-TNFα antibody were from Santa Cruz Biotechnology.

    Techniques: Expressing

    Orexin A (100 nmol L −1 ) treatment for 6 hours increases mRNA level of IL-6 , TNF -α and Fra1 in PC12-OX1R, but not in PC12-OX2R and PC12 cells. * P

    Journal: Acta physiologica (Oxford, England)

    Article Title: Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats

    doi: 10.1111/apha.12963

    Figure Lengend Snippet: Orexin A (100 nmol L −1 ) treatment for 6 hours increases mRNA level of IL-6 , TNF -α and Fra1 in PC12-OX1R, but not in PC12-OX2R and PC12 cells. * P

    Article Snippet: Primary antibodies rabbit anti-OX1R and rabbit anti-OX2R were products of Alomone laboratories (Jerusalem, Israel); mouse anti-Fra1 antibody and mouse anti-TNFα antibody were from Santa Cruz Biotechnology.

    Techniques:

    Orexin A treatment increases mRNA levels of PICs and Fra1 in PC12-OX1R cells. (A) Incubation of PC12-OX1R cells with orexin A for 6 hours resulted in a dose-dependent increase in mRNA levels of IL-6 , TNF -α and Fra1 with maximum increase occurring in 100 nmol/L orexin A treatment. (B) Orexin A (100 nmol/L) stimulation caused time-dependent increase in mRNA level of IL-6 , TNF -α and Fra1 in PC12-OX1R cells. (c) AP1 blocker curcumin (50 μmol L −1 ) attenuates the increase in the mRNA levels of PICs induced by orexin A. * P

    Journal: Acta physiologica (Oxford, England)

    Article Title: Orexin A increases sympathetic nerve activity through promoting expression of proinflammatory cytokines in Sprague Dawley rats

    doi: 10.1111/apha.12963

    Figure Lengend Snippet: Orexin A treatment increases mRNA levels of PICs and Fra1 in PC12-OX1R cells. (A) Incubation of PC12-OX1R cells with orexin A for 6 hours resulted in a dose-dependent increase in mRNA levels of IL-6 , TNF -α and Fra1 with maximum increase occurring in 100 nmol/L orexin A treatment. (B) Orexin A (100 nmol/L) stimulation caused time-dependent increase in mRNA level of IL-6 , TNF -α and Fra1 in PC12-OX1R cells. (c) AP1 blocker curcumin (50 μmol L −1 ) attenuates the increase in the mRNA levels of PICs induced by orexin A. * P

    Article Snippet: Primary antibodies rabbit anti-OX1R and rabbit anti-OX2R were products of Alomone laboratories (Jerusalem, Israel); mouse anti-Fra1 antibody and mouse anti-TNFα antibody were from Santa Cruz Biotechnology.

    Techniques: Incubation